Myeloma News and Research

RSS

New therapy for transplant rejection

Researchers in the U.S. have discovered a new cancer drug which effectively treats transplant rejections.

29 Dec 2008

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.

18 Dec 2008

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.

14 Dec 2008

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease.

14 Dec 2008

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

10 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Effects of stem cell source and patient age on stem cell transplantation outcomes

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

Researchers focus on phosphoinositide 3-kinase pathway in cancer research

Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN ).

5 Dec 2008

Declines in cancer incidence and death rates across U.S.

A new report from the nation's leading cancer organizations shows that, for the first time since the report was first issued in 1998, both incidence and death rates for all cancers combined are decreasing for both men and women, driven largely by declines in some of the most common types of cancer.

25 Nov 2008

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

Strong relationship found between allergies and cancer in environmentally exposed tissues

There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study.

12 Nov 2008

On the trail of a targeted therapy for blood cancer

Investigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.

12 Oct 2008

Researchers explore issues related to multiple myeloma treatment

Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.

6 Oct 2008

Myeloma News and Research

New therapy for transplant rejection

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

Doxil and docetaxel combination treatment delays disease progression in metastatic breast cancer

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Xencor presents data on anti-CD19 and anti-CD40 antibodies

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

Effects of stem cell source and patient age on stem cell transplantation outcomes

Novel therapeutic approaches for various forms of thrombocytopenia

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Researchers focus on phosphoinositide 3-kinase pathway in cancer research

Declines in cancer incidence and death rates across U.S.

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Strong relationship found between allergies and cancer in environmentally exposed tissues

On the trail of a targeted therapy for blood cancer

Researchers explore issues related to multiple myeloma treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News